Walter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5088196/publications.pdf

Version: 2024-02-01

933447 794594 21 534 10 19 citations h-index g-index papers 21 21 21 679 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	Antidepressants versus placebo in major depression: an overview. World Psychiatry, 2015, 14, 294-300.	10.4	133
2	Are placebo controls necessary to test new antidepressants and anxiolytics?. International Journal of Neuropsychopharmacology, 2002, 5, 193-7.	2.1	115
3	Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987â€2013. World Psychiatry, 2017, 16, 181-192.	10.4	84
4	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. Lancet Regional Health - Europe, The, 2022, 12, 100253.	5.6	46
5	Decreased suicide rates in recent antidepressant clinical trials. Psychopharmacology, 2018, 235, 1455-1462.	3.1	27
6	The conundrum of depression clinical trials. International Clinical Psychopharmacology, 2018, 33, 239-248.	1.7	25
7	Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000–2009. Journal of Psychiatric Research, 2017, 94, 202-207.	3.1	22
8	Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. Journal of Psychiatric Research, 2014, 51, 88-92.	3.1	15
9	The Effect of Anticonvulsants on the Dexamethasone Suppression Test. Canadian Journal of Psychiatry, 1989, 34, 441-443.	1.9	13
10	Magnitude and Pattern of Placebo Response in Clinical Trials of Oral Antihyperglycemic Agents: Data From the U.S. Food and Drug Administration, 1999–2015. Diabetes Care, 2018, 41, 994-1000.	8.6	13
11	Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. PLoS ONE, 2018, 13, e0193043.	2.5	8
12	Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews. Psychopharmacology, 2014, 231, 4301-4307.	3.1	6
13	Magnitude and pattern of placebo response in clinical trials of antiepileptic medications: Data from the Food and Drug Administration 1996–2016. Contemporary Clinical Trials, 2018, 64, 95-100.	1.8	6
14	Screening depressives for causative medical illness; the example of thyroid function testing: II. Hypothesis testing in ambulatory depressives. Depression, 1993, 1, 220-224.	0.6	4
15	Mortality Risk With Mirtazapine and Estimating Suicide Risk. JAMA Psychiatry, 2015, 72, 949.	11.0	4
16	The Impact of Underpowered Studies on Clinical Trial Results. American Journal of Psychiatry, 2018, 175, 188-188.	7.2	4
17	Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia. World Journal of Biological Psychiatry, 2020, 21, 64-71.	2.6	4
18	The placebo effect in psychiatric practice. Current Psychiatry, 2017, 16, 29-34.	1.7	3

WALTER

#	Article	IF	CITATIONS
19	Response to letter from Lipsitz etÂal Journal of Psychiatric Research, 2014, 57, 180-181.	3.1	2
20	Reply to Millman and Opler. Journal of Psychiatric Research, 2015, 61, 243-244.	3.1	0
21	Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements. Psychopharmacology Bulletin, 2021, 51, 79-108.	0.0	O